WO2004060878A3 - Inhibiteurs de phosphatases - Google Patents

Inhibiteurs de phosphatases Download PDF

Info

Publication number
WO2004060878A3
WO2004060878A3 PCT/US2003/041661 US0341661W WO2004060878A3 WO 2004060878 A3 WO2004060878 A3 WO 2004060878A3 US 0341661 W US0341661 W US 0341661W WO 2004060878 A3 WO2004060878 A3 WO 2004060878A3
Authority
WO
WIPO (PCT)
Prior art keywords
phosphatases
inhibitors
compositions
compounds
methods
Prior art date
Application number
PCT/US2003/041661
Other languages
English (en)
Other versions
WO2004060878A2 (fr
Inventor
Jeffrey O Saunders
Gregory F Miknis
Alexandre J Buckmelter
Kevin W Hunt
James F Blake
Guy P A Vigers
Xicheng Sun
Original Assignee
Vertex Pharma
Jeffrey O Saunders
Gregory F Miknis
Alexandre J Buckmelter
Kevin W Hunt
James F Blake
Guy P A Vigers
Xicheng Sun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma, Jeffrey O Saunders, Gregory F Miknis, Alexandre J Buckmelter, Kevin W Hunt, James F Blake, Guy P A Vigers, Xicheng Sun filed Critical Vertex Pharma
Priority to CA2511925A priority Critical patent/CA2511925C/fr
Priority to AU2003300114A priority patent/AU2003300114B9/en
Priority to US10/750,326 priority patent/US7439249B2/en
Priority to JP2004565845A priority patent/JP4619795B2/ja
Priority to EP03800372A priority patent/EP1583747A2/fr
Publication of WO2004060878A2 publication Critical patent/WO2004060878A2/fr
Publication of WO2004060878A3 publication Critical patent/WO2004060878A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne, d'une part des composés qui inhibent les phosphatases, d'autre part leurs compositions, et enfin des procédés permettant d'utiliser ces composés et compositions pour traiter des maladies.
PCT/US2003/041661 2002-12-31 2003-12-31 Inhibiteurs de phosphatases WO2004060878A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2511925A CA2511925C (fr) 2002-12-31 2003-12-31 Inhibiteurs de phosphatases
AU2003300114A AU2003300114B9 (en) 2002-12-31 2003-12-31 Inhibitors of phosphatases
US10/750,326 US7439249B2 (en) 2002-12-31 2003-12-31 Inhibitors of phosphatases
JP2004565845A JP4619795B2 (ja) 2002-12-31 2003-12-31 ホスファターゼのインヒビター
EP03800372A EP1583747A2 (fr) 2002-12-31 2003-12-31 Inhibiteurs de phosphatases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43757602P 2002-12-31 2002-12-31
US60/437,576 2002-12-31

Publications (2)

Publication Number Publication Date
WO2004060878A2 WO2004060878A2 (fr) 2004-07-22
WO2004060878A3 true WO2004060878A3 (fr) 2005-01-27

Family

ID=32713207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/041661 WO2004060878A2 (fr) 2002-12-31 2003-12-31 Inhibiteurs de phosphatases

Country Status (5)

Country Link
EP (1) EP1583747A2 (fr)
JP (1) JP4619795B2 (fr)
AU (1) AU2003300114B9 (fr)
CA (1) CA2511925C (fr)
WO (1) WO2004060878A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
TW200718687A (en) 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
WO2008133155A1 (fr) 2007-04-19 2008-11-06 Astellas Pharma Inc. Composé hétérocyclique bicyclique
FR2985258A1 (fr) * 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
CA2953482A1 (fr) 2013-07-03 2015-01-08 Indiana University Research & Technology Corporation Inhibiteurs de shp2 et methodes de traitement de maladies auto-immunes et associees a la glomerulonephrite a l'aide d'inhibiteurs de shp2
EP3801613A1 (fr) * 2018-06-04 2021-04-14 Bayer Aktiengesellschaft Inhibiteurs de shp2
CN111265529B (zh) * 2020-02-22 2021-07-23 南京大学 蛋白酪氨酸磷酸酶shp2抑制剂在制备治疗银屑病药物中的应用
CN111333628B (zh) * 2020-04-20 2022-05-10 大连医科大学附属第一医院 吲哚类生物碱、制备方法及作为降血糖药物的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0456835A1 (fr) * 1989-12-11 1991-11-21 Kyorin Pharmaceutical Co., Ltd. Derive de l'acide quinazoline-3-alcanoique, sels derives de ce compose et sa production
WO1995015963A1 (fr) * 1993-12-07 1995-06-15 Basf Aktiengesellschaft Derives du bicyclene, preparation et utilisation
WO1998018781A2 (fr) * 1996-10-28 1998-05-07 Versicor, Inc. Banques combinatoires de 2,4-pyrimidinediones fusionnes et 2,4-pyrimidinediones fusionnes actifs biologiquement
WO1998056770A1 (fr) * 1997-06-13 1998-12-17 Basf Aktiengesellschaft Procede de preparation de diones de quinazoline sur la phase gazeuse et leur utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080772A (en) * 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
WO2001004103A1 (fr) * 1999-07-13 2001-01-18 F. Hoffmann-La Roche Ag Benzazepinones et quinazolines
GB0022079D0 (en) * 2000-09-08 2000-10-25 Inst Of Molecul & Cell Biology Novel protein tyrosine phosphatase inhibitor
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0456835A1 (fr) * 1989-12-11 1991-11-21 Kyorin Pharmaceutical Co., Ltd. Derive de l'acide quinazoline-3-alcanoique, sels derives de ce compose et sa production
WO1995015963A1 (fr) * 1993-12-07 1995-06-15 Basf Aktiengesellschaft Derives du bicyclene, preparation et utilisation
WO1998018781A2 (fr) * 1996-10-28 1998-05-07 Versicor, Inc. Banques combinatoires de 2,4-pyrimidinediones fusionnes et 2,4-pyrimidinediones fusionnes actifs biologiquement
WO1998056770A1 (fr) * 1997-06-13 1998-12-17 Basf Aktiengesellschaft Procede de preparation de diones de quinazoline sur la phase gazeuse et leur utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. GORDEEV ET AL.: "a general and efficient solid phase synthesis of quinazoline-2,4-diones.", TETRAHEDRON LETTERS., vol. 38, no. 10, 1997, NLELSEVIER SCIENCE PUBLISHERS, AMSTERDAM., pages 1729 - 32, XP004054978 *
M. MALAMAS: "quinazolineacetic acids and related analogues as aldose reductase inhibitors.", JOURNAL OF MEDICINAL CHEMISTRY., vol. 34, no. 4, 1991, USAMERICAN CHEMICAL SOCIETY. WASHINGTON., pages 1492 - 503, XP002296377 *

Also Published As

Publication number Publication date
AU2003300114B9 (en) 2009-11-26
AU2003300114A1 (en) 2004-07-29
AU2003300114B2 (en) 2009-07-23
CA2511925A1 (fr) 2004-07-22
JP4619795B2 (ja) 2011-01-26
CA2511925C (fr) 2012-11-13
JP2006514658A (ja) 2006-05-11
EP1583747A2 (fr) 2005-10-12
WO2004060878A2 (fr) 2004-07-22

Similar Documents

Publication Publication Date Title
WO2007079164A3 (fr) Inhibiteurs de protéines kinases
WO2007026251A3 (fr) Utilisation d'inhibiteurs combines c-kit/fgfr3 pour le traitement du myelome multiple
WO2006071960A3 (fr) Compositions et procedes de traitement de troubles de la proliferation cellulaire
WO2003073999A3 (fr) Composes de modulation de pin1 et procedes d'utilisation correspondant
WO2002096361A3 (fr) Derives de 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone utilises comme inhibiteurs de kinase
WO2004100881A3 (fr) Preparation et utilisation de derives d'aryl alkyl acide pour le traitement de l'obesite
WO2008033562A3 (fr) Composés inhibiteurs de kinases
WO2003074550A3 (fr) Composes de modulation de pin1 et procedes d'utilisation correspondant
WO2007139960A3 (fr) Composés modulant l'activité de hsp90 et méthodes d'identification de ces composés
WO2004046120A3 (fr) Diaminotriazoles convenant comme inhibiteurs de proteine kinases
WO2004096234A3 (fr) Analogues de phosphonate inhibiteurs de kinase
WO2005030791A3 (fr) Inhibiteurs du canal potassique d'isoquinolinone
WO2003074500A3 (fr) Nouveaux composes
WO2005046603A3 (fr) Composes pyridiniques
WO2005030129A3 (fr) Inhibiteurs des canaux potassiques a la quinoleine
WO2007059230A3 (fr) 1h-benzimidazole-4-carboxamides substitues efficaces en tant qu’inhibiteurs de parp
WO2003105840A3 (fr) Inhibiteurs de sphingosine kinase
WO2005117846A3 (fr) Traitement de maladies a l'aide d'inhibiteurs de l'ice
WO2004030620A3 (fr) Inhibiteurs de tyrosine kinase
WO2000043373A3 (fr) Inhibiteurs de kinase
WO2005117939A3 (fr) Utilisation de ligands gpcr54 pour le traitement de l'infertilite
WO2005046578A3 (fr) Inhibiteurs du canal potassique isoquinolinone
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2006034391A3 (fr) Inhibiteurs d'indole de 15-lipoxygenase
WO2003084475A3 (fr) Inhibiteurs de l'interaction proteine-proteine s100-p53 et methode d'inhibition du cancer utilisant lesdits inhibiteurs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2511925

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004565845

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003300114

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003800372

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003800372

Country of ref document: EP